Screener
LABD vs CURE
Direxion Daily S&P Biotech Bear 3X Shares vs Direxion Daily Healthcare Bull 3X Shares
Key differences
- CURE costs 0.13% less per year.
- LABD follows a inverse strategy; CURE uses leveraged.
- Over the last 3 years, CURE has delivered higher annualized returns.
Side-by-side comparison
| LABD | CURE | |
|---|---|---|
| Annual cost (TER) | 1.07% | 0.94% |
| Fund size (AUM) | $69M | $138M |
| Since | 2015 | 2011 |
| Dividend yield | 6.38% | 1.33% |
| Asset class | equity | equity |
| Region | north america | north america |
| Strategy | inverse | leveraged |
| CAGR 1Y | -82.9% | +31.7% |
| CAGR 3Y | -50.8% | +0.8% |
| CAGR 5Y | -42.0% | +0.7% |
| Sharpe 3Y | -0.52 | 0.14 |
| Volatility 1Y | 74.72% | 42.92% |
| Max drawdown | -99.98% | -69.19% |
Green dot indicates the better value for that metric. Performance data is historical and does not predict future results.
Similar to LABD and CURE
Explore further